Anti cd122

Manufactured by BioLegend

Sourced in United Kingdom

Anti-CD122 is a monoclonal antibody that binds to the CD122 (IL-2Rβ) receptor, which is expressed on various immune cells, including natural killer (NK) cells, regulatory T cells, and memory T cells. This antibody can be used for the detection and analysis of CD122-expressing cells in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

CD122 (3 citations)

4 protocols using anti cd122

CD4+ Naïve T Cell Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

RPMI1640 medium containing 10% FCS was used for CD4 naïve T cell cultures. The following antibodies were purchased from BD BioSciences (San Jose, CA): anti-mouse CD3 (145-2C11), anti-mouse CD28 (37.51), anti-mouse IL-2, anti-CD4-PerCP, anti-CD4-PECy7, anti-CD8-FITC, anti-CD25-APC, anti-CD25-PE, anti-CD44-FITC, anti-CD62L-PE, anti-BrdU-FITC. Anti-FoxP3-APC, anti-IFNγ-APC, and anti-IL-17A-PE were from eBioscience (San Diego, CA). Anti-Helios, anti-CD122 and anti-GITR were from Biolegend (San Diego, CA). Recombinant mouse IL-2 and IL-7 were purchased from R&D Systems (Minneapolis, MN) and ovalbumin was from Sigma-Aldrich (St Louis, MO).

Liu C., Wang H.C., Yu S., Jin R., Tang H., Liu Y.F., Ge Q., Sun X.H, & Zhang Y. (2014). Id1 expression promotes T regulatory cell differentiation by facilitating TCR costimulation. Journal of immunology (Baltimore, Md. : 1950), 193(2), 663-672.

+ Open protocol

+ Expand

NK Cell Depletion and Characterization in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two different NK-depleting antibodies, anti-asialo GM1 (Wako) and anti-CD122 (BioLegend), were tested for their ability to deplete pNKs and/or uNKs in vivo in order to generate mice deficient in both MCs and NKs. The efficiency of pNK depletion was analyzed by flow cytometry. The presence or absence of uNKs was assessed by uNK-specific Dolichos biflorus agglutinin (DBA) lectin staining of implantations at gd10. For the anti-asialo GM1 treatment, C57BL/6J females were mated and anti-asialo GM1 (100 μL, 0.29 mg) was administered i.p. at gd0, 2, 4, 6 and 8. Control females received 100 μL of normal rabbit serum (Life Technologies) at the same time points. For the anti-CD122 treatment, anti-CD122 (250 μL, 0.25 mg) was administered i.p. to C57BL/6J females once at gd0, immediately after the detection of the copulation plug. Control females received PBS (250 μL), as previously described59 (link)60 (link). Mice were sacrificed at gd10 or gd18 and different organs were analyzed by flow cytometry to assess the pNKs; implantation sections from gd10 were analyzed by DBA lectin-specific staining to assess uNKs.

Meyer N., Woidacki K., Knöfler M., Meinhardt G., Nowak D., Velicky P., Pollheimer J, & Zenclussen A.C. (2017). Chymase-producing cells of the innate immune system are required for decidual vascular remodeling and fetal growth. Scientific Reports, 7, 45106.

+ Open protocol

+ Expand

Comprehensive Antibody Panel for Cell Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary antibodies used in this study include anti-DYKDDDDK Tag (CST, D6W5B, # 15009), anti-CD36 (BioLegend, # 336206), anti-KIR3DL1 (BioLegend, # 312716), anti-anti-KIR3DL2 (R&D, # FAB2878A), anti-anti-KIR3DL3 (R&D, # FAB8919r), anti-KIR2DL2/L3 (BioLegend, # 312612), anti-CD122 (BioLegend, # 105912), anti-CD5 (BioLegend, # 364016), anti-CD25 (BioLegend, 302610), anti-CD272 (BioLegend, # 344510), anti-CD2 (BioLegend, # 300214), anti-CD28 (BioLegend, # 302912), anti-CD80 (BioLegend, # 305219), anti-CD45 (BioLegend, # 304012), anti-IL6ST (BioLegend, # 362006), anti-CD276 (BioLegend, # 351006), anti-CD47 (BioLegend, # 323124). These antibodies were used at 1:100 dilution in MACS staining buffer (Miltenyi).

Siepe D.H., Henneberg L.T., Wilson S.C., Hess G.T., Bassik M.C., Zinn K, & Garcia K.C. (2022). Identification of orphan ligand-receptor relationships using a cell-based CRISPRa enrichment screening platform. eLife, 11, e81398.

+ Open protocol

+ Expand

Evaluating Maternal Immune Regulation in Mice

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

This study was carried out in accordance with the recommendations of the Ministery of Saxony-Anhalt, Germany. The protocol was approved by the “Landesverwaltungsamt Sachsen Anhalt: 42502-2-1296UniMD.” Mice were housed in our barrier facility with a 12-h light/dark cycle and received food and water ad libitum. MC-deficient C57BL/6J-Cpa3^Cre/+ (Cpa3^Cre/+) mice and their WT controls C57BL/6J-Cpa3^+/+ (Cpa3^+/+) were kindly provided by HR Rodewald (Heidelberg, Germany) (16 (link)) and bred in our facilities. 6- to 8-week-old females were allogeneically mated with BALB/c males (Charles River). The day of vaginal plug detection was defined as gestation day (gd) 0. Cpa3^Cre/+ females receive 0.25 mg (250 µl) anti-CD122 (BioLegend, London, United Kingdom) via intraperitoneal injection immediately after the detection of the copulation plug, to deplete peripheral and uNKs as described previously (17 (link)). Depletion of peripheral NKs with anti-CD122 was confirmed until gd18 (18 days after application) by analysis of different organs by flow cytometry. Additionally, uNKs absence was confirmed at gd10 (10 days after application) via Dolichos biflorus agglutinin staining (17 (link)). Control Cpa3^+/+ females received 250 µl PBS. Females underwent ultrasound imaging at gd5, 8, 10, 12, and 14 and were sacrificed at gd14.

Meyer N., Schüler T, & Zenclussen A.C. (2018). Simultaneous Ablation of Uterine Natural Killer Cells and Uterine Mast Cells in Mice Leads to Poor Vascularization and Abnormal Doppler Measurements That Compromise Fetal Well-being. Frontiers in Immunology, 8, 1913.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!